Biohaven Ltd. BHVN
Set alert
At close
Pre-market · Nov 3, 7:01 AM ET
- YTD
- +34.28%
- 1 year
- +2.09%
- Open
- 15.98
- Prev close
- 15.42
- Mkt cap
- 2.29B
- Vol
- 2.59M
- Avg vol
- 3.18M
- EPS
- -3.77
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 15.08
- High
- 16.11
- Forward P/E
- -8.11
- Beta
- 3.13
- Short ratio
- 7.20
- Inst. own
- 95.74%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 1, 2027
- 50-d avg
- 13.62
- 200-d avg
- 12.23
- 1y target
- 23.33
5D chart
Events in this range
- Oct 29, 2026Earnings: -0.86; estimate -0.78333; surprise -9.79%
- Oct 30, 2026Rating: Canaccord Genuity · Buy → Buy
Signals (119)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 3:55 PM | 15 hours ago |
| SMA: Bullish | Nov 2, 3:45 PM | 15 hours ago |
| MACD: Sell Signal | Nov 2, 3:40 PM | 15 hours ago |
| SMA: Bearish | Nov 2, 3:30 PM | 15 hours ago |
| SMA: Bearish | Nov 2, 3:25 PM | 15 hours ago |
| SMA: Bullish | Nov 2, 2:50 PM | 16 hours ago |
| SMA: Bearish | Nov 2, 2:20 PM | 16 hours ago |
| MACD: Buy Signal | Nov 2, 2:10 PM | 17 hours ago |
| MACD: Sell Signal | Nov 2, 12:05 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 12:00 PM | 19 hours ago |
| MACD: Buy Signal | Nov 2, 11:50 AM | 19 hours ago |
| SMA: Bullish | Nov 2, 11:30 AM | 19 hours ago |
| SMA: Bearish | Nov 2, 10:50 AM | 20 hours ago |
| MACD: Sell Signal | Nov 2, 10:35 AM | 20 hours ago |
| SMA: Bearish | Nov 2, 10:30 AM | 20 hours ago |
| SMA: Bullish | Nov 2, 10:20 AM | 20 hours ago |
| RSI: Overbought | Nov 2, 9:30 AM | 21 hours ago |
| SMA: Bullish | Oct 30, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:45 PM | 3 days ago |
Newest 20 of 119.
Key statistics
- Market cap
- 2.29B
- Enterprise value
- 2.47B
- Trailing P/E
- 0.00
- Forward P/E
- -8.11
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -3.77
- Beta
- 3.13
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -229.34M
- Total cash
- 161.12M
- Total debt
- 300.44M
- Return on equity
- 0.00%
- Shares outstanding
- 151.06M
- Short % of float
- 15.16%
- 50-day average
- 13.62
- 200-day average
- 12.23
Analyst view
Consensus: buy
- Target (low)
- 9.00
- Target (mean)
- 23.33
- Target (high)
- 48.00
- Strong buy3
- Buy9
- Hold4
- Sell0
- Strong sell1
Next earnings
Mar 1, 2027
Expected Mar 1, 2027. Consensus EPS estimate -0.1691.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 1, 2027 | Dec 30, 2026 | -0.44 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | -0.78333 | -0.86 | -0.08 | -9.79% |
| Aug 10, 2026 | Jun 30, 2026 | -0.76098 | -0.91 | -0.15 | -19.58% |
| May 4, 2026 | Mar 31, 2026 | -0.86 | -0.88 | -0.02 | -2.33% |
| Mar 2, 2026 | Dec 31, 2025 | -1.22 | -1.21 | +0.01 | +0.82% |
| Nov 10, 2025 | Sep 30, 2025 | -1.91 | -1.64 | +0.27 | +14.14% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 23, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Sep 10, 2026 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Sep 8, 2026 | RBC Capital | down | Outperform | Sector Perform |
| Aug 12, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Aug 11, 2026 | RBC Capital | main | Outperform | Outperform |
About Biohaven Ltd.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- biohaven.com
News
- Canaccord Genuity Maintains Buy on Biohaven, Raises Price Target to $32
- Biohaven Q3 Adj. EPS $(0.73) Beats $(0.74) Estimate
- Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
- Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Trade
- Biohaven Presents Preclinical Data For BHV-1420 At American Society Of Nephrology Kidney Week 2026
- RBC Capital Maintains Sector Perform on Biohaven, Raises Price Target to $22
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday
- Biohaven Rebounds With FDA Review Date for Rare Disease Drug
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
Your note
Sign in to keep a note on BHVN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAILEY GREGORY HUGH | Director | Purchase | Nov 12, 2025 | 2,020,070 |
| BUTEN MATTHEW | Chief Financial Officer | Conversion of Exercise of derivative security | Jan 4, 2026 | 195,652 |
| CAR BRUCE | Officer | Conversion of Exercise of derivative security | Jan 4, 2026 | 37,715 |
| CHILDS JOHN W | Director | Purchase | Nov 12, 2025 | 0 |
| CLARK GEORGE C. | Officer | Conversion of Exercise of derivative security | Jan 4, 2026 | 86,978 |
| CORIC VLADIMIR | Chief Executive Officer | Conversion of Exercise of derivative security | Jan 4, 2026 | 3,849,350 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.75% | 13,210,585 | 200.01M | Jun 29, 2026 |
| Montanova Capital LLC | 6.81% | 10,286,937 | 155.74M | Jun 29, 2026 |
| Stifel Financial Corporation | 6.58% | 9,941,165 | 150.51M | Jun 29, 2026 |
| Jupiter Topco LLC | 5.68% | 8,584,675 | 129.97M | Jun 29, 2026 |
| Woodline Partners LP | 5.07% | 7,660,280 | 115.98M | Jun 29, 2026 |
| State Street Corporation | 4.60% | 6,947,034 | 105.18M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.45% | 3,699,312 | 56.01M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.29% | 3,455,073 | 52.31M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.44% | 2,180,096 | 33.01M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.99% | 1,489,215 | 22.55M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.97% | 1,459,506 | 22.10M | Jul 30, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 0.88% | 1,333,088 | 20.18M | Jun 29, 2026 |